1
40
6
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2741/1572" target="_blank" rel="noreferrer noopener">http://doi.org/10.2741/1572</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
790-798
Volume
10
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The LEAPS approach to vaccine development
Publisher
An entity responsible for making the resource available
Frontiers in Bioscience
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-01
Subject
The topic of the resource
beta-2-microglobulin; binding-site; Biochemistry & Molecular Biology; Cell Biology; class-ii molecules; dc; dendritic cells; flt3 ligand fl; herpes simplex virus; HIV; human; immune responses; in-vivo; LEAPS constructs; major histocompatibility complex; peptide; protection; review; t-lymphocytes; th1 immune-responses; vaccines
Creator
An entity primarily responsible for making the resource
Zimmerman D H; Rosenthal K S
Description
An account of the resource
The Ligand Epitope Antigen Presentation System ( L. E. A. P. S. TM) approach to vaccine development utilizes immune peptides to promote the immunogenicity and influence the type of immune response generated towards epitopes in peptides which may be too small to elicit an immune response. The covalent attachment of these immune peptides to the antigenic peptide promotes the interaction of the epitope with T cells ( T cell binding ligand (TCBL)) or antigen presenting cells ( immune cell binding ligand (ICBL)) and ultimately promotes binding with the T cell receptor on CD4 or CD8 T cells. The "J" ICBL/TCBL peptide derived from the beta-2-microglobulin chain of MHC I molecules promotes Th1 type responses to the antigenic peptide while the "G" ICBL/TCBL peptide derived from the beta chain of MHC II molecules promotes Th2 types of responses. The efficacy of this approach has been demonstrated by characterization of the immune responses to L. E. A. P. S. vaccines and by elicitation of protection from infectious challenge with herpes simplex virus and other pathogens. The protection studies show that the L. E. A. P. S. approach allows customization of the immune response appropriate for inducing protection from disease. The theory, background, examples and studies of the mechanism of action of the L. E. A. P. S. vaccines will be discussed.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2741/1572" target="_blank" rel="noreferrer noopener">10.2741/1572</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2005
beta-2-microglobulin
binding-site
Biochemistry & Molecular Biology
Cell Biology
class-ii molecules
dc
dendritic cells
flt3 ligand fl
Frontiers in Bioscience
herpes simplex virus
HIV
Human
immune responses
in-vivo
Journal Article
LEAPS constructs
major histocompatibility complex
peptide
protection
review
Rosenthal K S
T-Lymphocytes
th1 immune-responses
Vaccines
Zimmerman D H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.vaccine.2010.06.043" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.vaccine.2010.06.043</a>
Pages
5533–5542
Issue
34
Volume
28
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.
Publisher
An entity responsible for making the resource available
Vaccine
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-08
Subject
The topic of the resource
*Antigen Presentation; Adoptive Transfer; Animals; Cells; Cultured; Dendritic Cells/*immunology; Epitopes; Female; gag Gene Products; Herpes Simplex/immunology/prevention & control; Herpesvirus 1; Human Immunodeficiency Virus/immunology; Human/immunology; Inbred A; Inbred C57BL; Interferon-gamma/immunology; Interleukin-12/immunology; Mice; T-Lymphocyte/immunology; Th1 Cells/*immunology; Viral Envelope Proteins/immunology; Viral Vaccines/*immunology
Creator
An entity primarily responsible for making the resource
Taylor P R; Koski G K; Paustian C C; Bailey E; Cohen P A; Moore F B-G; Zimmerman D H; Rosenthal K S
Description
An account of the resource
The Ligand Epitope Antigen Presentation System (LEAPS) converts a peptide containing a T cell epitope as small as 8 amino acids into an immunogen and directs the nature of the subsequent response. Tandem synthesis of the J peptide (a peptide from the beta-2-microglobulin) with peptides of 15 or 30 amino acids from HSV-1 or HIV made them immunogenic and promoted Th1 immune responses. Immunization of A/J or C57BL/6 mice with J-LEAPS heteroconjugates containing an epitope from the HSV-1 glycoprotein D (JgD) or an epitope from the HIV gag protein (JH) emulsified with Seppic ISA51 induced increased levels of IL-12p70 by day 3 and increased levels of interferon gamma (IFN-gamma) on days 10 and 24. Interestingly, levels of IL-10, TNF-alpha, and IL-6 did not change. Neither the H nor the gD peptides alone elicited responses and only weak responses followed immunization with the J peptide. Bone marrow (BM) cells became CD86 and CD11c positive within 48 h of treatment with JgD or JH. JH or JgD treatment promoted
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.vaccine.2010.06.043" target="_blank" rel="noreferrer noopener">10.1016/j.vaccine.2010.06.043</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Antigen Presentation
2010
Adoptive Transfer
Animals
Bailey E
Cells
Cohen P A
Cultured
Dendritic Cells/*immunology
Epitopes
Female
gag Gene Products
Herpes Simplex/immunology/prevention & control
Herpesvirus 1
Human Immunodeficiency Virus/immunology
Human/immunology
Inbred A
Inbred C57BL
Interferon-gamma/immunology
Interleukin-12/immunology
Koski G K
Mice
Moore F B-G
Paustian C C
Rosenthal K S
T-Lymphocyte/immunology
Taylor P R
Th1 Cells/*immunology
Vaccine
Viral Envelope Proteins/immunology
Viral Vaccines/*immunology
Zimmerman D H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.intimp.2009.12.016" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.intimp.2009.12.016</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
412-421
Issue
4
Volume
10
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model
Publisher
An entity responsible for making the resource available
International Immunopharmacology
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-04
Subject
The topic of the resource
acellular pertussis-vaccine; auto-immune; beta-chain; binding-site; Collagen induced arthritis; identification; immune responses; immunogenicity; Immunology; inflammation; peptide analog; Pharmacology & Pharmacy; Regulation of cytokines in autoimmunity; regulatory t-cells; rheumatoid-arthritis; Therapeutic vaccine; transgenic mice; Vaccines for autoimmunity
Creator
An entity primarily responsible for making the resource
Zimmerman D H; Taylor P; Bendele A; Carambula R; Duzant Y; Lowe V; O'Neill S P; Talor E; Rosenthal K S
Description
An account of the resource
The mouse model of collagen induced arthritis (CIA) effectively mimics human disease and thus is useful for testing and development of rheumatoid arthritis (RA) therapies. We developed a Ligand Epitope Antigen Presentation System (LEAPS) peptide hetero-conjugate vaccine containing an epitope of human collagen type II (CEL-2000) that acted as a therapeutic vaccine in the collagen induced arthritis (CIA) mouse model. LEAPS technology converts a small peptide containing a disease specific epitope into an immunogen by attaching it to an immune or T cell binding peptide (I/TCBL). For CEL-2000, a peptide from human collagen type II (254-273) is attached to the I/TCBL peptide from human in microglobulin (J). Treatment with CEL-2000 limited disease (CIA) progression, as demonstrated by reduced Arthritic Index (AI) score, and footpad swelling. Efficacy was confirmed by histopathological microscopic examination of tissues at the end of the study. CEL-2000 limited disease progression as well or better than the etanercept (Enbrel) therapeutic control with significantly better histopathological results than the etanercept treated mice. Most interestingly, CEL-2000 therapy modulated serum cytokine levels with an increase in IL-12p70 and IL-10, which are not seen with etanercept therapy, and reduced IL-17 and INF-alpha, also seen with etanercept, among other cytokines studied. CEL-2000 was safe and well tolerated for the mice that received 5 injections given every 2 weeks in a 90 day study supporting its potential usage for long term therapy. These studies demonstrate that fewer treatments with CEL-2000 provide therapy at least as effective as etanercept by specifically modulating the disease producing autoimmune response. (C) 2010 Elsevier B.V. All rights reserved.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.intimp.2009.12.016" target="_blank" rel="noreferrer noopener">10.1016/j.intimp.2009.12.016</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2010
acellular pertussis-vaccine
auto-immune
Bendele A
beta-chain
binding-site
Carambula R
Collagen induced arthritis
Duzant Y
identification
immune responses
immunogenicity
Immunology
Inflammation
International Immunopharmacology
Journal Article
Lowe V
O'Neill S P
peptide analog
Pharmacology & Pharmacy
Regulation of cytokines in autoimmunity
regulatory t-cells
rheumatoid-arthritis
Rosenthal K S
Talor E
Taylor P
Therapeutic vaccine
Transgenic mice
Vaccines for autoimmunity
Zimmerman D H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
n/a
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
A374-A374
Issue
4
Volume
19
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cel-1000, A New Type Of Immunemodulator, Protects Mice Against Infection With A Dna And An Rna Virus That Cause Encephalitis
Publisher
An entity responsible for making the resource available
Faseb Journal
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-03
Subject
The topic of the resource
Biochemistry & Molecular Biology; Cell Biology; Life Sciences & Biomedicine - Other; Topics
Creator
An entity primarily responsible for making the resource
Goel N; Zimmerman D H; Rosenthal K S
Identifier
An unambiguous reference to the resource within a given context
n/a
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2005
Biochemistry & Molecular Biology
Cell Biology
Faseb Journal
Goel N
Life Sciences & Biomedicine - Other
Rosenthal K S
Topics
Zimmerman D H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.vaccine.2003.11.062" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.vaccine.2003.11.062</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
2368-2373
Issue
19
Volume
22
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
CEL-1000 - a peptide with adjuvant activity or Th1 immune responses
Publisher
An entity responsible for making the resource available
Vaccine
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-06
Subject
The topic of the resource
Research & Experimental Medicine; Immunology; cytokines; antibodies; beta-2-microglobulin; vaccines; dna; antigens; CEL-1000; epitope; gamma interferon; IgG2a antibodies; liposomes
Creator
An entity primarily responsible for making the resource
Charoenvit Y; Goel N; Whelan M; Rosenthal K S; Zimmerman D H
Description
An account of the resource
CEL-1000 (derG, DGQEEKAGVVSTGLIGGG) is a small immunomodulatory peptide which delivers demonstrated protective activity in two infectious disease challenge models (HSV and malaria) and an allogenic tumor vaccine model. CEL-1000 and other activators (defensin-beta, CpG ODN, and imiquimod) of the innate immune system promote IFN-gamma-associated protective responses. CEL-1000 is an improved form of peptide G (a peptide from human MHC II beta chain second domain, aa 135-149) known to enhance immune responses of other immunogenic peptides. Since defensin-P, CpG ODN, and imiquimod have been shown to possess adjuvant activity, we investigated the adjuvant effect of peptide G and CEL-1000 as conjugates with HIV and malaria peptides. Antibody titers and isotypes were evaluated on serum taken from select days following immunization. Results for CEL-1000 and G peptide conjugates were compared with results for KLH conjugates of the same HIV peptide from the p 17 molecule (87-116) referred to as HGP-30. Studies demonstrated that comparable titers were seen on day 28, 42, 63, and 77 with either G or KLH-HGP-30 peptide conjugates. In another study, CEL-1000 conjugates (CEL-1000-HGP-30) demonstrated a 4-10-fold higher titer antibody response than seen with several other peptide conjugates of the same HGP-30 peptide. Improved adjuvant activity of CEL-1000 in peptide conjugates was also demonstrated by a shift in the antibody isotypes toward a Th1 response (IgG2a). The IgG2a/IgG1, ratio for G-HGP-30 HIV or KLH-HGP-30 HIV conjugates were lower than for the CEL-1000-HGP-30 HIV conjugate. A similar favoring of the IgG2a/IgG1 ratio was seen for a malaria peptide conjugate (CEL-1000-SF/GF) compared to the un-conjugated peptide (SF-GF). CEL-1000 also showed adjuvant activity in an allogenic tumor vaccine model. As expected for an adjuvant, CEL-1000 or G does not induce detectable self-directed or cross reactive antibodies. CEL-1000 is currently being investigated for use as an adjuvant with conventional vaccines. It is expected that IgG2a antibodies would be preferably generated by CEL-1000 adjuvancy and could enhance in vivo clearance of antigens or pathogens. (C) 2004 Elsevier Ltd. All rights reserved.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.vaccine.2003.11.062" target="_blank" rel="noreferrer noopener">10.1016/j.vaccine.2003.11.062</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2004
Antibodies
Antigens
beta-2-microglobulin
CEL-1000
Charoenvit Y
Cytokines
DNA
epitope
gamma interferon
Goel N
IgG2a antibodies
Immunology
Journal Article or Conference Abstract Publication
liposomes
Research & Experimental Medicine
Rosenthal K S
Vaccine
Vaccines
Whelan M
Zimmerman D H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
n/a
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
A65-A65
Issue
3
Volume
57
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
An immunomodulating peptide (CEL-1000) elicits protection against HSV-1
Publisher
An entity responsible for making the resource available
Antiviral Research
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
2003-02
Subject
The topic of the resource
Pharmacology & Pharmacy; Virology
Creator
An entity primarily responsible for making the resource
Rosenthal K S; Goel N; Zimmerman D H
Identifier
An unambiguous reference to the resource within a given context
n/a
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2003
Antiviral research
Goel N
Journal Article
Pharmacology & Pharmacy
Rosenthal K S
Virology
Zimmerman D H